Key Highlights

  • QuidelOrtho (NASDAQ:QDEL) booked third-quarter 2026 Revenue of USD 619 million, a 12% decline, and unveiled a cost program aimed at more than USD 80 million of annual savings in 2027.
  • Fresenius Medical Care (NYSE:FMS) saw third-quarter Operating Income excluding special items slip 6% at constant currency and tightened 2026 growth guidance to the lower half of its earlier range.
  • Amwell (NYSE:AMWL) collected USD 23.9 million in subscription fees during the third quarter, down from USD 30.9 million a year earlier.
  • InnovAge (NASDAQ:INNV) recorded external provider costs and cost of care equal to roughly 76% of revenue for the three months ended September 30, 2026.

QuidelOrtho (NASDAQ:QDEL): Restructuring Target Follows a Revenue Slide

QuidelOrtho (NASDAQ:QDEL), a diagnostics maker, released third-quarter results on November 3, 2026, covering the quarter that ended September 27. Sales came in at USD 619 million, which is 12% below USD 699.9 million, with China pricing changes and a milder respiratory season cited as drags. Labs revenue dipped 6% to USD 353 million, and Point of Care revenue fell 27% to USD 120 million. A GAAP net loss of USD 53.8 million sat beside adjusted EBITDA of USD 148 million. Free Cash Flow reached only USD 0.3 million, and against cash of USD 166.4 million the company carries about USD 2.94 billion of borrowings, arithmetic on two Balance Sheet lines. The new program reorganizes the Business around two units and targets more than USD 80 million of yearly savings in 2027, with one-time charges of USD 30 to 35 million landing in the fourth quarter. Full-year 2026 revenue guidance now stands at USD 2.52 to 2.54 billion, down from USD 2.52 to 2.60 billion. Net interest expense climbed to USD 55.4 million from USD 46.1 million. Savings remain a goal rather than a result, and restructuring can disrupt operations at QuidelOrtho (NASDAQ:QDEL).

Fresenius Medical Care (NYSE:FMS): Reimbursement Shift Pushes Guidance Lower

Fresenius Medical Care (NYSE:FMS) walked through its third-quarter 2026 numbers on an Earnings Call held November 3, 2026, the first one led by CEO Shervin Korangy. Group revenue held roughly steady, while operating income excluding special items dropped 6% at constant currency, leaving an Operating Margin of 11%. Management now sees 2026 operating income growth between flat and negative mid-single digits, which sits in the lower half of the earlier guidance. TDAPA, a temporary Medicare add-on payment for new dialysis medicines, has swung from a tailwind into a headwind, and that pressure builds in the fourth quarter. Inflation is now projected to run above the EUR 300 million upper bound of the original range. Special items netted to a negative EUR 161 million. Recent FDA audits at company sites produced corrective and preventive actions, though the call offered no quantification. By September 30, 2026, EUR 357 million had gone toward the second EUR 1 billion buyback, purchasing 9.1 million shares, or 3.4% of share capital. Net Leverage held at 2.6x, and the first buyback Tranche of up to EUR 600 million should finish by mid-December. A more complete 2027 outlook arrives in February.

Amwell (NYSE:AMWL): Subscription Income Weakens While Visit Fees Grow

A Form 10-Q for the quarter ended September 30, 2026 came from Amwell (NYSE:AMWL) on November 3, 2026. Subscription fees collected totaled USD 23.9 million, compared with USD 30.9 million in the third quarter of 2025, a decline of about 23% by simple arithmetic. Across nine months, subscription fees reached USD 74.6 million against USD 103.6 million a year earlier. Visit fees from services delivered through its affiliated medical group ran the other way, increasing to USD 23.7 million from USD 21.2 million. The platform is sold on subscription, usually under three-year contracts with recurring fees tied to members who have access, while the medical group collects fee-for-service payments per episode of care. The extract ended before the income statement, so total revenue, net loss and cash are unreported here, and the reason for the subscription drop was not provided. The filing lists a loss history, a small number of major clients, and uncertainty over whether the Defense Health Agency relationship continues past the fourth quarter of 2026 on similar terms. The platform handled about 2.7 million visits over nine months, and Amwell (NYSE:AMWL) flags Cybersecurity Liability as a concern.

InnovAge (NASDAQ:INNV): Two State Pauses Meet Care Costs Near 76% of Revenue

Reporting the three months to September 30, 2026, InnovAge (NASDAQ:INNV) put out its filing on November 3, 2026. It operates Programs of All-Inclusive Care for the Elderly, arrangements under which the company takes full financial responsibility for frail seniors' medical care in exchange for a fixed monthly payment from Medicare and Medicaid. About 8,420 participants are served through 20 centers in six states. External provider costs and cost of care totaled approximately 76% of revenue. California and Colorado have each placed a hold on new PACE applications and expansions, lasting through at least November 19, 2027 and October 31, 2028 respectively. Management expects a Colorado Medicaid premium rate cut, applied retroactively to July 1, 2026. The extract lacked revenue, Net Income and cash figures, so none can be reported. A corrective action plan in California is still under way. Voluntary disenrollment has averaged 6.5% a year across three fiscal years. The average participant risk adjustment Factor score reached 2.51, measured against a 1.0 baseline. Provider cost increases are forecast to begin in the second half of fiscal 2027, with wage-linked rate strain expected in certain states.

Where Things Stand

QuidelOrtho (NASDAQ:QDEL) can push its savings program only as far as execution allows, because revenue fell 12% and cash generation was thin. At Fresenius Medical Care (NYSE:FMS), reimbursement support is weakening while inflation runs ahead of plan. Amwell (NYSE:AMWL) has seen recurring subscription income shrink while visit fees grew. InnovAge (NASDAQ:INNV) remains exposed to wages and provider costs under fixed monthly payments, and its extract gave no revenue figure. Each name runs a different business, so the balance of evidence is cautious rather than conclusive.